EGFR and non-small cell lung carcinoma: Mok et al. compared an irreversible EGFR‐TKI, dacomitinib, with a reversible EGFR‐TKI, gefitinib, in treatment‐naïve patients with EGFR‐mutant NSCLC, finding better PFS with dacomitinib than with gefitinib (14.7 vs. 9.2 months; HR, 0.59; 95% CI: 0.47 to 0.74; P < 0.001).11